Detection method of combbutrol calcium related substances
Through the combination of high-performance liquid chromatography and specific mobile phases, the irreversible adsorption of anions to the chromatographic column and pH sensitivity caused by reagents is solved, and the efficient and accurate detection of cobutre calcium is achieved, which extends the column life and improves the Stability of the test results.
Patent Information
- Application Number
- CN202410975469.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-22
AI Technical Summary
In the existing cobutre calcium detection methods, anions have irreversible adsorption and pH sensitivity to reagents, which affects the service life and detection accuracy of the chromatographic column.
High performance liquid chromatography was used to use anion embedded alkyl-bonded porous silica gel as a filler, and the mobile phase consisted of potassium dihydrogen phosphate buffered saline solution and acetonitrile. It was detected through a gradient elution procedure to avoid the use of ion-to-reagent reagents.
It realizes simple, fast and accurate detection of cobutre calcium, extends the service life of the chromatographic column, and improves the stability and reliability of the detection results.
Smart Images

Figure CN119000910A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug analysis, and in particular to a method for detecting calcobutrol-related substances. Background Art
[0002] Calcium calcobutrol, a calcium coordination compound composed of calcium and the macrocyclic ligand dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid (butrol), is one of the excipients of the contrast agent gadobutrol. Its function is to prevent the release of free gadolinium from gadobutrol in gadobutrol injection, thereby solving the safety problem of nephrogenic systemic fibrosis caused by the toxicity of gadolinium cation.
[0003]
[0004] In view of the high polarity of calcobutrol and its lack of retention on a C18 chromatographic column, the detection methods disclosed in the existing patent documents CN106187930A, CN113272284A, and CN114573522A use a chromatographic column with ordinary octadecyl bonded silica as a filler, and a mobile phase of sodium octane sulfonate monohydrate / acetonitrile / water or sodium pentane sulfonate / acetonitrile / water system. By adding anion pairing reagents sodium octane sulfonate or sodium pentane sulfonate to the mobile phase, the nitrogen-containing compound is ionized and positively charged under acidic conditions, and the retention of calcobutrol on the chromatographic column is enhanced by electrostatic action, thereby realizing the detection and analysis of the sample. However, the anion pair reagent added in this detection method has the following defects: (1) it will produce irreversible adsorption on the chromatographic column, thereby affecting the active sites of the chromatographic column; (2) it is difficult to rinse it from the chromatographic column, causing irreversible damage to the chromatographic column and greatly shortening the service life of the chromatographic column; (3) it is sensitive to pH value, so the pH value accuracy of the mobile phase is required to be high; (4) the concentration of the ion pair reagent has a great influence on the retention time of the detection sample. Summary of the invention
[0005] In view of the above situation, the present invention provides a method for detecting calcobutrol and related substances. The method adopts high performance liquid chromatography and can simply, quickly and accurately analyze and detect calcobutrol and its related substances by selecting specific chromatographic detection conditions, thereby ensuring the quality controllable of calcobutrol and its preparations.
[0006] The technical solution adopted by the present invention is as follows: A method for detecting a substance related to calcobutrol, wherein the substance is gadobutrol monohydrate, and the method is a high performance liquid chromatography method, and the detection conditions are as follows: Chromatographic column: Anion embedded alkyl bonded porous silica gel as filler; Mobile phase: consists of mobile phase A and mobile phase B, wherein mobile phase A is potassium dihydrogen phosphate buffer solution, and mobile phase B is acetonitrile.
[0007] The mobile phase elution program of the high performance liquid chromatography is a gradient elution program, and the gradient elution program is as shown in Table 1 below: Table 1 .
[0008] Preferably, the mobile phase A is a potassium dihydrogen phosphate buffer solution with a pH value of (1-2).
[0009] More preferably, the mobile phase A is a potassium dihydrogen phosphate buffer solution with a pH of 1.7.
[0010] Preferably, the detection conditions of the high performance liquid chromatography method also include: a detection wavelength of 196 nm, a flow rate of 0.9-1.1 ml / min, a column temperature of 35-45° C., and an injection volume of 15-25 μL.
[0011] Preferably, the detection conditions of the high performance liquid chromatography method also include: a detection wavelength of 196 nm, a flow rate of 1.0 ml / min, a column temperature of 40° C., and an injection volume of 20 μL.
[0012] The detection method of calcobutrol-related substances comprises the following steps: (1) Preparation of solution: a. Prepare a localization solution of gadobutrol monohydrate; b. preparing an impurity mixed solution containing colbutrol calcium and gadobutrol monohydrate; c. Prepare the test solution of calcobutrol calcium; d. Prepare the control solution of the test solution of calcobutrol; (2) Detection: The positioning solution in step a, the impurity mixed solution in step b, the calcobutrol test solution in step c, and the control solution in step d are respectively injected into a high performance liquid chromatograph for detection. The chromatographic conditions are as follows: Chromatographic column: Anion embedded alkyl bonded porous silica gel is used as filler. Mobile phase: It is composed of mobile phase A and mobile phase B. The mobile phase A is a potassium dihydrogen phosphate buffer solution with a pH of 1.7, and the mobile phase B is acetonitrile. Detection wavelength: 196nm, Flow rate: 1.0ml / min, Column temperature: 40°C, Injection volume: 20 μL, The mobile phase elution program of the high performance liquid chromatography is a gradient elution program, and the gradient elution program is shown in Table 1: (3) Analytical chromatogram: According to the chromatograms of the test solution and the control solution, the content of gadobutrol monohydrate in the test sample was calculated. The calculation formula for each content of the impurities was: .
[0013] The beneficial effects of the present invention are as follows: The detection method provided by the present invention adopts high performance liquid chromatography, selects a chromatographic column with an anion embedded alkyl bonded porous silica gel as a filler, and selects a potassium dihydrogen phosphate / acetonitrile / water system as a mobile phase, which can solve the retention problem of calcobutrol on the chromatographic column, and does not use an ion pair reagent, thereby avoiding the irreversible damage of the ion pair reagent to the chromatographic column, and also avoiding the problem of the ion pair reagent introducing miscellaneous peaks under the condition of terminal absorption (190-200nm), and the operation is simple, the measurement results are stable and reliable, and the specificity is strong. The detection method provided by the present invention can be used for the quality detection of calcobutrol, ensures its quality, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] The accompanying drawings are used to provide an understanding of the technical solution of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the technical solution of the present invention and do not constitute a limitation to the technical solution of the present invention.
[0015] Figure 1 The HPLC spectra of the blank solution, test solution and control solution in Comparative Example 1 are superimposed.
[0016] Figure 2 This is the HPLC spectrum of the mobile phase pH=2.5 in Example 1.
[0017] Figure 3 This is the HPLC spectrum of the mobile phase pH=1.7 in Example 1.
[0018] Figure 4 This is the HPLC spectrum of the mobile phase pH=1.5 in Example 1.
[0019] Figure 5 This is the HPLC spectrum under the conditions of elution procedure 1 in Example 2.
[0020] Figure 6 This is the HPLC spectrum under the conditions of elution procedure 2 in Example 2.
[0021] Figure 7 This is the HPLC spectrum under the conditions of elution procedure 3 in Example 2.
[0022] Figure 8 This is the HPLC spectrum under the conditions of elution procedure 4 in Example 2.
[0023] Fig. 9 This is the HPLC spectrum under the conditions of elution procedure 5 in Example 2.
[0024] Fig.10 This is the HPLC spectrum under the conditions of elution program 6 in Example 2.
[0025] Fig.11 This is the linear graph of gadobutrol monohydrate in Example 6.
[0026] Fig.12 This is the linear graph of colbutrol calcium in Example 6. DETAILED DESCRIPTION
[0027] To make the purpose, technical solution and advantages of the present invention more clear, the embodiments of the present invention will be described in detail below. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other arbitrarily without conflict.
[0028] The raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products.
[0029] Comparative Example 1 1. Chromatographic conditions: Column: Kromasil 100-5 C18 250×4.6 mm, 5 μm; Detection wavelength: UV-196nm Flow rate: 1.0ml / min Column temperature: 30°C Injection volume: 20 μl Run time: 35 minutes Mobile phase: It is composed of phase A and phase B. Phase A is 0.2% sodium pentane sulfonate solution (pH=1.5 adjusted with phosphoric acid), and phase B is acetonitrile. The volume ratio of the two is 97:3.
[0030] 2. Solution preparation Diluent: mobile phase; Blank solution: diluent; Gadobutrol monohydrate stock solution: weigh 34.41 mg of gadobutrol monohydrate, place in a 10 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0031] Gadobutrol monohydrate localization solution: accurately measure 0.5 ml of the above-mentioned gadobutrol monohydrate stock solution, place it in a 50 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0032] Test solution: Accurately weigh 36.14 mg of colbutrol calcium, place in a 10 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0033] Mixed solution: Accurately measure 0.5 ml of the above-mentioned gadobutrol monohydrate stock solution and the test solution, place them in the same 50 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0034] Control solution: Accurately measure 1 ml of the above test solution, place it in a 100 ml volumetric flask, dilute to the scale with diluent, shake well, and obtain.
[0035] Wherein, the concentration of each substance in the above mixed solution is as follows: Calcobutrol: 35 μg / ml Gadobutrol monohydrate: 35 μg / ml 3. Sample injection analysis Take the blank solution, test solution and control solution and inject them into the high performance liquid chromatograph, and perform the detection and analysis under the above chromatographic conditions to obtain the following Figure 1 HPLC profile shown.
[0036] Conclusion: The ion pair reagent (sodium pentane sulfonate solution) was used as mobile phase A. Because it introduced impurity peaks under the terminal absorption condition (190-200 nm), the chromatogram obtained after blank solution injection had impurity peaks at the elution point of gadobutrol monohydrate (see Figure 1 This will interfere with the quantitative detection results of gadobutrol monohydrate, so the chromatographic conditions in Comparative Example 1 need to be optimized.
[0037] Example 1 Optimization of chromatographic column and mobile phase pH Considering that calcobutrol has a strong polarity and is almost not retained on an ordinary C18 chromatographic column, the prior art, when analyzing calcobutrol-related substances, will choose to add ion pair reagents to the mobile phase to enhance the retention of calcobutrol on the chromatographic column and improve the peak shape, thereby achieving the purpose of qualitative and quantitative detection and analysis of calcobutrol-related substances.
[0038] However, the present invention has found in experiments that when an ion pair reagent (sodium pentane sulfonate solution) is used as the mobile phase, the ion pair reagent will introduce impurity peaks under the terminal absorption (190-200 nm) condition (see the chromatogram of Comparative Example 1), thereby affecting the detection and analysis results of the related substances of calcobutrol. At the same time, it is also found that the use of a mixed mode chromatographic column (such as a Comixsil HCS chromatographic column) and the use of a potassium dihydrogen phosphate / acetonitrile / water system as the mobile phase can solve both the retention problem of calcobutrol on the chromatographic column and the problem of impurity peaks introduced by the ion pair reagent under the terminal absorption (190-200 nm) condition.
[0039] After determining to use the mixed mode chromatographic column, the present invention also conducted the following screening test on the pH value of the mobile phase: 1. Chromatographic conditions: Table 2
[0040] 2. The gradient elution procedure is as follows: Table 3
[0041] 3. Solution preparation Diluent: 60% methanol Blank solution: diluent Gadobutrol monohydrate stock solution: accurately weigh 10.66 mg of gadobutrol monohydrate, place in a 20 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0042] System suitability solution: Accurately weigh 100.47 mg of colbutrol calcium and place it in a 10 ml volumetric flask. Add diluent to dissolve it. Then add 1 ml of the above-mentioned gadobutrol monohydrate stock solution. Add diluent to dilute to the scale and shake well.
[0043] 4. Sample injection analysis The blank solution and the system suitability solution were respectively transferred into the high performance liquid chromatograph, and the detection and analysis were performed under the above chromatographic conditions and elution program conditions.
[0044] Conclusion: The results of HPLC analysis show that when the pH of the mobile phase is adjusted to 1.7, the separation effect of each peak is optimal. Finally, the optimal choice of mobile phase pH is determined to be pH=1.7 (see HPLC chromatogram Figures 2~4 ).
[0045] Example 2 Optimization of elution procedure 1. Chromatographic conditions: Column: Comixsil HCS, 4.6×250 mm, 5 μm Detection wavelength: UV-196nm Flow rate: 1.0ml / min Column temperature: 40°C Injection volume: 35 μl Mobile phase: It is composed of phase A and phase B. Phase A is potassium dihydrogen phosphate buffer solution (pH=1.7 adjusted with phosphoric acid), and phase B is acetonitrile.
[0046] 2. Solution preparation: Gadobutrol monohydrate stock solution: weigh 25.07 mg of gadobutrol monohydrate, place in a 50 ml volumetric flask, add acetonitrile to dissolve and dilute to the scale, shake well, and obtain.
[0047] Mixed solution: Weigh 200.27 mg of calcobutrol, place in a 20 ml volumetric flask, add acetonitrile to dissolve, then add 2 ml of the above-mentioned gadobutrol monohydrate stock solution, finally add the mobile phase to dilute to the scale, shake well, and obtain the mixed solution.
[0048] 3. Elution procedure (1) Elution procedure 1 (isocratic elution): Blank solution: mobile phase Mobile phase: potassium dihydrogen phosphate buffer solution (pH = 1.7 adjusted with phosphoric acid): acetonitrile = 60:40 (V / V) (2) Elution procedure 2: Table 4
[0049] (3) Elution procedure 3: Table 5
[0050] (4) Elution procedure 4: Table 6
[0051] (5) Elution procedure 5: Table 7
[0052] (6) Elution procedure 6: Table 8
[0053] 4. Sample injection analysis The mixed solution and the blank solution in elution procedure 1 were respectively injected into a high performance liquid chromatograph, and detection and analysis were performed under the above chromatographic conditions and each elution procedure.
[0054] Conclusion: (1) Under the conditions of elution procedure 1, the blank solution interferes with the peak of gadobutrol monohydrate, affecting the detection and analysis of gadobutrol monohydrate (see HPLC chromatogram Figure 5 ); (2) Under the conditions of elution procedures 2 to 5, gadobutrol monohydrate did not elute (see HPLC chromatogram Figures 6 to 9 However, when elution procedure 6 was used, gadobutrol monohydrate and cobutrol calcium could be effectively separated (see HPLC chromatogram Fig.10 ).
[0055] In summary, elution procedure 6 as an elution procedure in high performance liquid chromatography can effectively separate calcobutrol and gadobutrol monohydrate. In elution procedure 6, although the change trend of mobile phase A is similar to that of procedures 4-5, the mobile phase A is controlled to be a higher proportion of 40% at the beginning, which is significantly increased to 90% after a shorter time of 20 minutes, and then eluted at a higher proportion of 40% within a shorter elution time of 10 minutes in the later period, so that gadobutrol monohydrate and calcobutrol can be effectively separated in a shorter time of 30 minutes. This may be because the proportion of mobile phase A determined by elution procedure 6 is higher than that of elution procedures 2-5, thereby achieving effective separation of calcobutrol and gadobutrol monohydrate; at the same time, elution procedure 6 has a shorter elution time than elution procedures 2-5, and the detection sensitivity of gadobutrol monohydrate is increased by increasing the gradient change rate. Example 3 System suitability test 1. Chromatographic conditions: Chromatographic column: Anion embedded alkyl bonded porous silica gel as filler; Mobile phase: composed of mobile phase A and mobile phase B, wherein mobile phase A is potassium dihydrogen phosphate buffer solution with pH=1.7, and mobile phase B is acetonitrile; Detection wavelength: 196nm; Flow rate: 1.0ml / min; Column temperature: 40°C; Injection volume: 20 μl; Perform gradient elution according to the elution program in Table 1 below: 2. Solution preparation Diluent: Mobile phase A Test solution: accurately weigh 100.08 mg of colbutrone calcium sample, place it in a 10 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0056] Control solution: Accurately measure 1 ml of the above test solution, place it in a 100 ml volumetric flask, dilute to the scale with diluent, shake well, and obtain.
[0057] Gadobutrol monohydrate stock solution: accurately weigh 4.992 mg of gadobutrol monohydrate, place in a 10 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0058] System suitability solution: Accurately weigh 97.15 mg of colbutrol calcium sample, place in a 10 ml volumetric flask, add diluent to dissolve, then add 1 ml of the above-mentioned gadobutrol monohydrate stock solution, finally add diluent to dilute to the scale, shake well, and obtain.
[0059] Sensitivity solution: Accurately measure 50μl of the above test solution and place it in a 100ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0060] 3. Sample injection analysis The system suitability solution and sensitivity solution were injected once, and the control solution was injected 6 times continuously for detection and analysis. The system suitability test results are shown in Table 9 below.
[0061] Table 9 System suitability results
[0062] Conclusion: In the system suitability test, gadobutrol monohydrate and calcobutrol eluted in sequence with a separation of 10.5 (>6.0) and a theoretical plate number of 2925 (≥2000) according to calcobutrol. In the sensitivity test, the signal-to-noise ratio of the chromatographic peak of calcobutrol was 38 (≥10), and the RSD of the main peak area of the 6-point reference solution was 1% (RSD (n=6)<10%), both of which met the acceptable standards.
[0063] Example 4 Specificity Test 1. Chromatographic conditions: Same as Example 3 2. Solution preparation Diluent: Mobile phase A Blank solution: diluent Gadobutrol monohydrate stock solution ①: Accurately weigh 10.034 mg of gadobutrol monohydrate, place in a 100 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0064] Gadobutrol monohydrate localizing solution: Accurately measure 11 ml of the above-mentioned gadobutrol monohydrate stock solution ①, place it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0065] Gadobutrol monohydrate stock solution ②: Accurately weigh 10.44 mg of gadobutrol monohydrate, place in a 100 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0066] Specific solution: Accurately weigh 98.46 mg of calcobutrol sample, place it in a 10 ml volumetric flask, add diluent to dissolve, then add 1 ml of gadobutrol monohydrate stock solution ②, add diluent to dilute to the scale, shake well, and obtain.
[0067] 3. Sample injection analysis The blank solution, gadobutrol monohydrate positioning solution, and specific solution were sampled once for detection and analysis. The specificity test results are shown in Table 10 below.
[0068] Table 10 Specificity test results name Retention time Separation Gadobutrol monohydrate 6.723 10.1 Calcobutrol 12.770 NA Conclusion: The results in the above table show that the blank solution does not interfere with the detection of the main component peak and impurity peak, and the separation between the chromatographic peaks is greater than 1.5, which meets the acceptable standard, indicating that the method has good specificity.
[0069] Example 5 Precision Test 1. Chromatographic conditions: Same as Example 3 2. Solution preparation (1) Repeatability test (Laboratory 1) Diluent: Mobile phase A Gadobutrol monohydrate stock solution: prepare the same gadobutrol monohydrate stock solution ② as in Example 4 under the item “Specificity test”.
[0070] Spiked test solution ①~⑥: Accurately weigh 6 samples of calcobutrol (①102.28 mg, ②102.51 mg, ③103.64 mg, ④102.38 mg, ⑤102.57 mg, ⑥102.45 mg), respectively, place them in 10 ml volumetric flasks, add diluent to dissolve, then add 1 ml of the above-mentioned gadobutrol monohydrate stock solution respectively, and then add diluent to dilute to the scale, shake well, and obtain.
[0071] Control solution ①~⑥: Accurately measure 1 ml of each of the above-mentioned spiked test solutions ①~⑥, place them in 100 ml volumetric flasks, add diluent to dilute to the scale, shake well, and obtain.
[0072] (2) Reproducibility test (Laboratory 2) Diluent: Mobile phase A Gadobutrol monohydrate stock solution: accurately weigh 10.48 mg of gadobutrol monohydrate, place in a 100 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0073] Spiked test solution ①~⑥: Accurately weigh 6 samples of calcobutrol, with the sample amounts being ①103.98 mg, ②101.01 mg, ③100.97 mg, ④97.36 mg, ⑤103.06 mg, and ⑥100.58 mg, respectively, and place them in 10 ml volumetric flasks, add diluent to dissolve, then add 1 ml of the above-mentioned gadobutrol monohydrate stock solution, add diluent to dilute to the scale, shake well, and obtain.
[0074] Control solution ①~⑥: Accurately measure 1 ml of the above-mentioned spiked test solution ①~⑥ respectively, place them in 100 ml volumetric flasks, add diluent to dilute to the scale, shake well, and obtain.
[0075] 3. Sample injection analysis The spiked test solutions ①~⑥ and control solutions ①~⑥ from Laboratory 1 and Laboratory 2 were injected once for detection and analysis. The results of the repeatability test and the reproducibility test are shown in Table 11 and Table 12, respectively.
[0076] Table 11 Repeatability test results Serial number Single impurity content (%) Total impurity content (%) 1 0.028 0.028 2 0.027 0.027 3 0.028 0.029 4 0.029 0.027 5 0.027 0.027 6 0.028 0.028 RSD% 2 2 Table 12 Reproducibility test results
[0077] in conclusion: It can be seen from Table 3 that in the repeatability test, the RSDs of the single impurity content and the total impurity content of the spiked test solution were both 2% (≤15%), which met the acceptable standard and the method had good repeatability.
[0078] It can be seen from Table 4 that in the reproducibility test, the RSDs of the single impurity content and the total impurity content of the spiked test solution were both 3% (≤20%), which met the acceptable standard and the method had good reproducibility.
[0079] Example 6 Linearity Test 1. Chromatographic conditions: Same as Example 3 2. Solution preparation (1) Linearity test of gadobutrol monohydrate Gadobutrol monohydrate stock solution: prepare the same gadobutrol monohydrate stock solution ① as in Example 4 “Specificity Test”.
[0080] 40% linear solution: Accurately measure 1 ml of the above-mentioned gadobutrol monohydrate stock solution and place it in a 25 ml volumetric flask. Add diluent to dilute to the scale and shake well to obtain the solution.
[0081] 80% linear solution: Accurately measure 2 ml of the above-mentioned gadobutrol monohydrate stock solution, place it in a 25 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0082] 100% linear solution: Accurately measure 1 ml of the above-mentioned gadobutrol monohydrate stock solution, place it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0083] 150% linear solution: Accurately measure 1.5 ml of the above-mentioned gadobutrol monohydrate stock solution and place it in a 10 ml volumetric flask. Add diluent to dilute to the scale and shake well.
[0084] 200% linear solution: Accurately measure 2 ml of the above-mentioned gadobutrol monohydrate stock solution, place it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0085] (2) Calcium cobutyrol linearity test Calcobutrol calcium stock solution: Accurately weigh 21.08 mg of Calcobutrol calcium, place in a 20 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0086] 40% linear solution: Accurately measure 1 ml of the above-mentioned calcobutrol stock solution and place it in a 25 ml volumetric flask. Add diluent to dilute to the scale and shake well.
[0087] 80% linear solution: Accurately measure 2 ml of calcobutrol stock solution, place it in a 25 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0088] 100% linear solution: Accurately measure 1 ml of the above-mentioned calcobutrol stock solution, place it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0089] 150% linear solution: Accurately measure 1.5 ml of the above-mentioned calcobutrol stock solution, place it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0090] 200% linear solution: Accurately measure 2 ml of the above-mentioned calcobutrol stock solution, place it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0091] 3. Sample injection analysis Each of the above linear solutions was sampled once for detection and analysis. The linear test results are shown in Table 13 below.
[0092] Table 13 Linearity test results
[0093] Conclusion: The results in the above table show that gadobutrol monohydrate has a good linear relationship with the peak area in the concentration range of 3.108~19.426μg / mL, the linear equation is y=0.0280x-0.0049, and the correlation coefficient is r=0.999; calcobutrol has a good linear relationship with the peak area in the concentration range of 1.302~203.422μg / mL, the linear equation is y=0.0966x+0.0006, and the correlation coefficient is r=0.999.
[0094] Example 7 Limit of Quantitation Test 1. Chromatographic conditions: Same as Example 3 2. Solution preparation Diluent: Mobile phase A Gadobutrol monohydrate stock solution: prepare the same gadobutrol monohydrate stock solution ① as in Example 4 “Specificity Test”.
[0095] Calcobutrol calcium stock solution: Accurately weigh 20.85 mg of Calcobutrol calcium, place in a 20 ml volumetric flask, add diluent to dissolve and dilute to the scale, shake well, and obtain.
[0096] Gadobutrol monohydrate quantification limit solution: Take 1 ml of the above-mentioned calcobutrol stock solution, place it in a 25 ml volumetric flask, add diluent to dilute to the scale, shake well, and then take 0.8 ml of this solution and the above-mentioned gadobutrol monohydrate stock solution respectively, place them in the same 25 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0097] Calcium calcobutrol quantitative limit solution: Take 0.8 ml of 40% Calcium calcobutrol linear solution in the "Linearity test" of Example 6, put it in a 25 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0098] 3. Sample injection analysis The above-mentioned gadobutrol monohydrate limit of quantitation solution and cobutrol calcium limit of quantitation solution were sampled and injected 6 times for detection and analysis. The results of the limit of quantitation test are shown in Table 14 below.
[0099] Table 14 Quantitation limit results
[0100] Conclusion: The results in the above table show that the limit of quantification of gadobutrol monohydrate is 0.031%, the peak area RSD is 8% (≤15%), and the average signal-to-noise ratio S / N is 13 (≥10); the limit of quantification of calcobutrol is 0.013%, the peak area RSD is 11% (≤15%), and the average signal-to-noise ratio S / N is 15 (≥10). It can be seen that the analytical method for calcobutrol-related substances described in the present invention can accurately measure the content of gadobutrol monohydrate at a very low limit.
[0101] Example 8 Detection limit test 1. Chromatographic conditions: Same as Example 3 2. Solution preparation Diluent: Mobile phase A Gadobutrol monohydrate detection limit solution: Take 4 ml of the gadobutrol monohydrate limit solution in the "quantification limit test" of Example 7, put it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0102] Detection limit solution of Calcium Cobutrol: Take 4 ml of the quantification limit solution of Calcium Cobutrol under the "Quantification Limit Test" of Example 7, put it in a 10 ml volumetric flask, add diluent to dilute to the scale, shake well, and obtain.
[0103] 3. Sample injection analysis The above-mentioned gadobutrol monohydrate detection limit solution and cobutrol calcium detection limit solution were sampled once for detection and analysis. The detection limit test results are shown in Table 15 below.
[0104] Table 15 Detection limit test results name Detection limit concentration μg / ml Detection limit% S / N Gadobutrol monohydrate 1.2433 0.012 6 Calcobutrol 0.5208 0.0052 5 Conclusion: The results in the above table show that the detection limit of gadobutrol monohydrate is 0.012%, and the signal-to-noise ratio S / N is 6 (≥3); the detection limit of calcobutrol is 0.0052%, and the signal-to-noise ratio S / N is 5 (≥3). It can be seen that the analytical method for calcobutrol-related substances of the present invention can produce a response at an extremely low limit.
[0105] Example 9 Stability Test 1. Chromatographic conditions: Same as Example 3 2. Solution preparation Spiked test solution: the same as the spiked test solution① under the “Repeatability test” in Example 5.
[0106] Control solution: the same as control solution ① under the item “Repeatability test” in Example 5.
[0107] The data at the 0h time point are the data of the spiked test solution ① and the control solution ① under the "Repeatability test" in Example 5.
[0108] The above-mentioned spiked test solution and control solution were placed at 5℃±3℃ for inspection, and samples were injected for detection and analysis at 18h, 21h, 38h, and 52h to inspect the stability of the solution.
[0109] 3. Sample injection analysis The spiked test solution and control solution at each time point were sampled once for detection and analysis. The stability test results are shown in Table 16 below.
[0110] Table 16 Stability test results
[0111] Conclusion: The results in the above table show that the RSD of the peak area of the main component of the control solution at each time point is 1% (<10%), and the change rates of the single impurity content and the total impurity content in the spiked test solution compared with 0h are less than 20% (≤20%), which meets the acceptable standard. It can be seen that the control solution and the spiked test solution have good stability within 52 hours under 5℃±3℃.
[0112] Example 10 Durability Test 1. Chromatographic conditions: Same as Example 3 2. Solution preparation Diluent: Mobile phase A System suitability solution: the same as the system suitability solution under the item “System suitability test” in Example 3.
[0113] Sensitivity solution: the same as the sensitivity solution under the item “System suitability test” in Example 3.
[0114] Take 35 μl of the system suitability solution for injection analysis and adjust the chromatographic conditions according to Table 17: Table 17 Chromatographic adjustment scheme
[0115] 3. Sample injection analysis The above system suitability solution and sensitivity solution were taken and injected once under the above chromatographic conditions for detection and analysis. The results are shown in Table 18.
[0116] Table 18 Durability test results
[0117] Conclusion: After fine-tuning the chromatographic conditions, gadobutrol monohydrate and calcobutrol in the system suitability solution still eluted in sequence, with a separation greater than 10 (>6.0), and the number of theoretical plates based on calcobutrol was greater than 2700 (≥2000); and the signal-to-noise ratio of the chromatographic peak of calcobutrol in the sensitivity solution was greater than 35 (≥10). Therefore, the method provided by the present invention has good durability.
[0118] Example 11 Determination of the content of related substances in calcobutrol by HPLC 1. Chromatographic conditions: Same as Example 3 2. Solution preparation Three batches of calcobutrol samples were taken to prepare test solution, control solution and sensitivity solution. The preparation method was the same as the corresponding preparation process under "System suitability" in Example 3.
[0119] 3. Sample injection analysis Take one injection of each of the above solutions for analysis, and obtain the data results shown in Table 19 below: Table 19 Results of three batches of validation tests
[0120] Conclusion: The contents of single impurities and total impurities in the test samples did not exceed the limits, indicating that the three batches of samples met the quality standard requirements.
[0121] The technical solution of the present invention is explained through the above embodiments, but the present invention is not limited to the above embodiments, that is, it does not mean that the present invention must rely on the above specific embodiments to be implemented. Any improvements made by technicians in the relevant field based on the present invention, or equivalent replacement of the materials selected by the present invention, etc., fall within the scope of protection of the patent.
Claims
1. A method for detecting substances related to calcobutrol, characterized in that: The related substance is gadobutrol monohydrate, the method is high performance liquid chromatography, and the detection conditions are as follows: Chromatographic column: Anion embedded alkyl bonded porous silica gel as filler; Mobile phase: composed of mobile phase A and mobile phase B, wherein mobile phase A is potassium dihydrogen phosphate buffer solution, and mobile phase B is acetonitrile; The mobile phase elution program of the high performance liquid chromatography is a gradient elution program, and the gradient elution program is as shown in Table 1 below: Table 1 。 2. The method for detecting the related substances of calcobutrol according to claim 1, characterized in that: The mobile phase A is a potassium dihydrogen phosphate buffer solution with a pH value of (1-2).
3. The method for detecting the related substances of calcobutrol according to claim 2, characterized in that: The mobile phase A is a potassium dihydrogen phosphate buffer solution with a pH of 1.
7.
4. The method for detecting the related substances of calcobutrol according to claim 1 or 2, characterized in that: The detection conditions of the high performance liquid chromatography method also include: a detection wavelength of 196 nm, a flow rate of 0.9-1.1 ml / min, a column temperature of 35-45° C., and an injection volume of 15-25 μL.
5. The method for detecting the related substances of calcobutrol according to any one of claims 1 to 3, characterized in that: The detection conditions of the high performance liquid chromatography method also include: detection wavelength of 196 nm, flow rate of 1.0 ml / min, column temperature of 40° C., and injection volume of 20 μL.
6. A method for detecting a substance related to calcobutrol according to any one of claims 1 to 4, characterized in that: The detection method comprises the following steps: (1) Preparation of solution: a. Prepare a localization solution of gadobutrol monohydrate; b. preparing an impurity mixed solution containing colbutrol calcium and gadobutrol monohydrate; c. Prepare the test solution of calcobutrol calcium; d. Prepare the control solution of the test solution of calcobutrol; (2) Detection: The positioning solution in step a, the impurity mixed solution in step b, the calcobutrol test solution in step c, and the control solution in step d are respectively injected into a high performance liquid chromatograph for detection. The chromatographic conditions are as follows: Chromatographic column: Anion embedded alkyl bonded porous silica gel is used as filler. Mobile phase: It is composed of mobile phase A and mobile phase B. The mobile phase A is a potassium dihydrogen phosphate buffer solution with a pH of 1.7, and the mobile phase B is acetonitrile. Detection wavelength: 196nm, Flow rate: 1.0ml / min, Column temperature: 40°C, Injection volume: 20 μL, The mobile phase elution program of the high performance liquid chromatography is a gradient elution program, and the gradient elution program is shown in Table 1: (3) Analytical chromatogram: According to the chromatograms of the test solution and the control solution, the content of gadobutrol monohydrate in the test sample was calculated. The calculation formula for each content of the impurities was: 。
Citation Information
Patent Citations
High-purity calcobutrol preparing method
CN106187930A
Method for preparing calcobutrol
CN113272284A
Novel crystal form of combbutrol calcium and preparation method thereof
CN114573522A
